Review of Vaccinia Virus for Lung Cancer Therapy and Systemic Immunotherapy

Linkai Li authored a review article on figshare, last updated May 7, 2026. The 22 KB document discusses preclinical progress in using Vaccinia virus for lung cancer therapy, focusing on its potential as a systemic immunotherapy platform. It details evidence from lung cancer models, engineering strategies, and early clinical data.

Use Cases

• Reviewing preclinical evidence for Vaccinia virus efficacy in lung cancer models based on the description.
• Analyzing engineering strategies to convert 'cold' tumors into responsive ones based on the description.
• Evaluating obstacles like systemic delivery and immunosuppressive feedback for clinical translation based on the description.

Strengths

• The document is licensed under CC-BY-4.0, allowing open reuse.
• The author and specific last update date (2026-05-07 04:44:03) are provided.

Limitations

• The dataset is a single 22 KB document, indicating a limited scope of data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Freshness

Last updated 2026-05-07 04:44:03.